JP2019516789A - フルベストラント配合物およびその使用方法 - Google Patents

フルベストラント配合物およびその使用方法 Download PDF

Info

Publication number
JP2019516789A
JP2019516789A JP2019510578A JP2019510578A JP2019516789A JP 2019516789 A JP2019516789 A JP 2019516789A JP 2019510578 A JP2019510578 A JP 2019510578A JP 2019510578 A JP2019510578 A JP 2019510578A JP 2019516789 A JP2019516789 A JP 2019516789A
Authority
JP
Japan
Prior art keywords
microns
fulvestrant
suspension
pharmaceutical composition
aqueous
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019510578A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019516789A5 (enExample
Inventor
チェン、フェン−ジン
エル． クリル、スティーブン
エル． クリル、スティーブン
アブ シュメイス、ラマ
アブ シュメイス、ラマ
Original Assignee
イーグル ファーマスーティカルズ、インク．
イーグル ファーマスーティカルズ、インク．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by イーグル ファーマスーティカルズ、インク．, イーグル ファーマスーティカルズ、インク． filed Critical イーグル ファーマスーティカルズ、インク．
Publication of JP2019516789A publication Critical patent/JP2019516789A/ja
Publication of JP2019516789A5 publication Critical patent/JP2019516789A5/ja
Priority to JP2021118471A priority Critical patent/JP7312523B2/ja
Priority to JP2023086732A priority patent/JP2023109959A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2019510578A 2016-05-06 2017-05-05 フルベストラント配合物およびその使用方法 Pending JP2019516789A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2021118471A JP7312523B2 (ja) 2016-05-06 2021-07-19 フルベストラント配合物およびその使用方法
JP2023086732A JP2023109959A (ja) 2016-05-06 2023-05-26 フルベストラント配合物およびその使用方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662332842P 2016-05-06 2016-05-06
US62/332,842 2016-05-06
US201662420555P 2016-11-10 2016-11-10
US62/420,555 2016-11-10
PCT/US2017/031376 WO2017193048A1 (en) 2016-05-06 2017-05-05 Fulvestrant formulations and methods of their use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021118471A Division JP7312523B2 (ja) 2016-05-06 2021-07-19 フルベストラント配合物およびその使用方法

Publications (2)

Publication Number Publication Date
JP2019516789A true JP2019516789A (ja) 2019-06-20
JP2019516789A5 JP2019516789A5 (enExample) 2020-04-30

Family

ID=58709642

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019510578A Pending JP2019516789A (ja) 2016-05-06 2017-05-05 フルベストラント配合物およびその使用方法
JP2021118471A Active JP7312523B2 (ja) 2016-05-06 2021-07-19 フルベストラント配合物およびその使用方法
JP2023086732A Pending JP2023109959A (ja) 2016-05-06 2023-05-26 フルベストラント配合物およびその使用方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2021118471A Active JP7312523B2 (ja) 2016-05-06 2021-07-19 フルベストラント配合物およびその使用方法
JP2023086732A Pending JP2023109959A (ja) 2016-05-06 2023-05-26 フルベストラント配合物およびその使用方法

Country Status (15)

Country Link
US (2) US20190134059A1 (enExample)
EP (1) EP3452011A1 (enExample)
JP (3) JP2019516789A (enExample)
KR (1) KR102438425B1 (enExample)
CN (1) CN109310621A (enExample)
AU (2) AU2017261321B2 (enExample)
CA (1) CA3022834A1 (enExample)
CO (1) CO2018013257A2 (enExample)
IL (2) IL285928B2 (enExample)
MA (1) MA44862A (enExample)
MX (2) MX2018013414A (enExample)
MY (1) MY205661A (enExample)
UA (1) UA125514C2 (enExample)
WO (1) WO2017193048A1 (enExample)
ZA (1) ZA201807031B (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021502362A (ja) * 2017-11-08 2021-01-28 イーグル ファーマスーティカルズ、インク． フルベストラント製剤とその使用方法
JP2023504867A (ja) * 2019-12-11 2023-02-07 上海博志研新薬物技術有限公司 フルベストラント医薬組成物、その調製方法及び応用
JP2026500440A (ja) * 2022-12-29 2026-01-06 サムヤン、ホールディングス、コーポレーション 優れた薬物動態特性を有するフルベストラントの医薬組成物及びその製造方法

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11590077B2 (en) 2016-05-06 2023-02-28 Eagle Pharmaceuticals, Inc. Fulvestrant formulations and methods of their use
CN113694017B (zh) * 2020-05-11 2024-04-02 鲁南制药集团股份有限公司 一种氟维司群注射制剂及其制备方法
WO2022100750A1 (zh) * 2020-11-16 2022-05-19 北京厚燊维康科技有限责任公司 可用于光动力治疗或诊断的制剂
CN120284882A (zh) * 2020-12-10 2025-07-11 上海云晟研新生物科技有限公司 氟维司群药物组合物、其制备方法及应用
WO2023121232A1 (ko) * 2021-12-20 2023-06-29 주식회사 삼양홀딩스 용해도가 개선된 풀베스트란트의 약학 조성물 및 그 제조 방법

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003519659A (ja) * 2000-01-10 2003-06-24 アストラゼネカ アクチボラグ フルベストラント製剤
JP2004534093A (ja) * 2001-07-07 2004-11-11 アストラゼネカ アクチボラグ フルベストラントの筋肉内投与用の医薬製剤
TW201016220A (en) * 2008-10-31 2010-05-01 Scinopharm Taiwan Ltd Micronization form of 7α-[9-(4,4,5,5,5-pentafluoropentylsufinyl)nonyl]estra-1,3,5(10)-triene-3,17β-diol and process for the preparation thereof
JP2011514349A (ja) * 2008-03-07 2011-05-06 サイドース・エルエルシー フルベストラント配合物
JP2013503113A (ja) * 2009-08-31 2013-01-31 シーアン リーバン ファーマシューティカル テクノロジー シーオー．， エルティーディー． フルベストラントナノスフェア／ミクロスフェア並びにその調製方法及び使用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8853260B2 (en) * 1997-06-27 2014-10-07 Abraxis Bioscience, Llc Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
WO2001087262A2 (en) 2000-05-15 2001-11-22 Pharmacia Italia S.P.A. Stabilized steroidal suspension
US6495534B2 (en) * 2000-05-15 2002-12-17 Pharmacia & Upjohn Spa Stabilized aqueous suspensions for parenteral use
GB0116619D0 (en) * 2001-07-07 2001-08-29 Astrazeneca Ab Formulation
JP2003298516A (ja) 2002-03-29 2003-10-17 Fujitsu Ltd 波長分散補償装置
JP5513713B2 (ja) * 2004-08-04 2014-06-04 カムルス エービー 非層状分散を生じる組成物
CN101237857A (zh) 2005-05-09 2008-08-06 生物领域医疗公司 使用微球和非离子型造影剂的组合物和方法
EA015781B1 (ru) 2005-10-21 2011-12-30 Панацея Биотек Лимитед Композиции для лечения рака
US8158152B2 (en) 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
CN101108168B (zh) * 2007-08-03 2010-12-08 西安力邦医药科技有限责任公司 一种氟维司群缓释微球的制备方法
HRP20191104T1 (hr) 2007-09-25 2019-09-20 Solubest Ltd. Pripravci koji sadrže lipofilne aktivne spojeve i postupak za njihovu pripremu
EP2442789A1 (en) 2009-06-18 2012-04-25 Abbott Laboratories Stable nanoparticulate drug suspension
US20130280330A9 (en) * 2009-07-31 2013-10-24 Xi'an Libang Medical Technology Co., Ltd. Microsphere drug carrier, preparation method, composition and use thereof
WO2012021791A2 (en) 2010-08-13 2012-02-16 Scidose Llc Aqueous formulation with improved stability
CA2811258C (en) 2010-09-16 2019-10-15 Shimoda Biotech (Pty) Ltd Fulvestrant compositions and methods of use
EP2468258A1 (en) 2010-12-22 2012-06-27 LEK Pharmaceuticals d.d. Process for the preparation of a pharmaceutical composition comprising a low soluble pharmaceutically active ingredient
EP3925625A1 (en) 2011-01-09 2021-12-22 ANP Technologies, Inc. Hydrophobic molecule-induced branched polymer aggregates and their use
CA2836831C (en) * 2011-05-20 2015-06-02 Capital, Business Y Gestion De Finanzas S.L. Pharmaceutical composition
CN102915088A (zh) 2011-08-03 2013-02-06 鸿富锦精密工业（深圳）有限公司 资料存储器固定装置
CA2869377C (en) 2012-04-09 2022-11-08 Scidose, Llc Fulvestrant formulations
US11179468B2 (en) * 2012-04-09 2021-11-23 Eagle Pharmaceuticals, Inc. Fulvestrant formulations
CN104379163A (zh) 2012-06-08 2015-02-25 霍夫曼-拉罗奇有限公司 用于治疗癌症的磷酸肌醇3激酶抑制剂化合物和化疗剂的突变选择性及组合
CN104337761B (zh) * 2013-08-07 2019-03-26 江苏豪森药业集团有限公司 氟维司群药物组合物
WO2015033302A2 (en) * 2013-09-06 2015-03-12 Salah Uddin Ahmed Fulvestrant compositions
US20160287601A1 (en) * 2013-10-03 2016-10-06 Millennium Pharmaceuticals, Inc. Enhanced treatment regimens using pi3k inhibitors
HUP1300646A2 (en) 2013-11-12 2015-05-28 Druggability Technologies Ip Holdco Jersey Ltd Complexes of fulvestrant and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them
PT107433B (pt) 2014-01-28 2018-12-04 Hovione Farm S A Processo de redução e controlo do tamanho de partícula
US9271990B2 (en) 2014-02-14 2016-03-01 Fresenius Kabi Usa, Llc Fulvestrant formulations
WO2016004369A1 (en) 2014-07-02 2016-01-07 The Research Foundation For The State University Of New York Surfactant-stripped micelle compositions with high cargo to surfactant ratio
CN104434808A (zh) 2014-07-03 2015-03-25 石药集团中奇制药技术（石家庄）有限公司 一种治疗性纳米粒子及其制备方法

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003519659A (ja) * 2000-01-10 2003-06-24 アストラゼネカ アクチボラグ フルベストラント製剤
JP2004534093A (ja) * 2001-07-07 2004-11-11 アストラゼネカ アクチボラグ フルベストラントの筋肉内投与用の医薬製剤
JP2011514349A (ja) * 2008-03-07 2011-05-06 サイドース・エルエルシー フルベストラント配合物
TW201016220A (en) * 2008-10-31 2010-05-01 Scinopharm Taiwan Ltd Micronization form of 7α-[9-(4,4,5,5,5-pentafluoropentylsufinyl)nonyl]estra-1,3,5(10)-triene-3,17β-diol and process for the preparation thereof
JP2013503113A (ja) * 2009-08-31 2013-01-31 シーアン リーバン ファーマシューティカル テクノロジー シーオー．， エルティーディー． フルベストラントナノスフェア／ミクロスフェア並びにその調製方法及び使用

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021502362A (ja) * 2017-11-08 2021-01-28 イーグル ファーマスーティカルズ、インク． フルベストラント製剤とその使用方法
JP7220712B2 (ja) 2017-11-08 2023-02-10 イーグル ファーマスーティカルズ、インク． フルベストラント製剤とその使用方法
US12186427B2 (en) 2017-11-08 2025-01-07 Eagle Pharmaceuticals, Inc. Fulvestrant formulations and methods of their use
JP2023504867A (ja) * 2019-12-11 2023-02-07 上海博志研新薬物技術有限公司 フルベストラント医薬組成物、その調製方法及び応用
JP7497902B2 (ja) 2019-12-11 2024-06-11 上海雲晟研新生物科技有限公司 フルベストラント医薬組成物、その調製方法及び応用
JP2026500440A (ja) * 2022-12-29 2026-01-06 サムヤン、ホールディングス、コーポレーション 優れた薬物動態特性を有するフルベストラントの医薬組成物及びその製造方法

Also Published As

Publication number Publication date
AU2017261321B2 (en) 2023-03-09
US20210346396A1 (en) 2021-11-11
CO2018013257A2 (es) 2018-12-28
MY205661A (en) 2024-11-04
RU2018142068A3 (enExample) 2020-09-17
US12370199B2 (en) 2025-07-29
BR112018072768A2 (pt) 2019-02-19
KR20190005183A (ko) 2019-01-15
JP2023109959A (ja) 2023-08-08
RU2018142068A (ru) 2020-06-08
MX2018013414A (es) 2019-06-06
NZ747911A (en) 2025-03-28
ZA201807031B (en) 2023-10-25
AU2023203392A1 (en) 2023-06-29
KR102438425B1 (ko) 2022-09-01
US20190134059A1 (en) 2019-05-09
EP3452011A1 (en) 2019-03-13
MX2022013199A (es) 2022-12-13
CA3022834A1 (en) 2017-11-09
IL262465A (en) 2018-12-31
IL285928B1 (en) 2025-02-01
UA125514C2 (uk) 2022-04-13
IL285928B2 (en) 2025-06-01
CN109310621A (zh) 2019-02-05
MA44862A (fr) 2019-03-13
AU2017261321A1 (en) 2018-11-15
IL285928A (en) 2021-10-31
JP7312523B2 (ja) 2023-07-21
JP2021169510A (ja) 2021-10-28
WO2017193048A1 (en) 2017-11-09

Similar Documents

Publication Publication Date Title
JP7312523B2 (ja) フルベストラント配合物およびその使用方法
JP3977418B2 (ja) 飽和溶解度と溶解速度を増大させた薬剤投与用ナノ懸濁液
JP2008509120A (ja) 非層状分散を生じる組成物
ES2884849T3 (es) Composiciones de profármaco de aripiprazol
JP7026609B2 (ja) 微細粒子含有組成物およびその製法
CN105012236A (zh) 一种长效非水载体注射液及其制备方法
ES2929437T3 (es) Método para preparación de nanopartículas
CN1794975A (zh) 使抗微生物的药物有效抗通常认为抗该药物的生物体的制剂
JP7157830B2 (ja) アリピプラゾールプロドラッグ組成物
RU2775225C2 (ru) Составы фульвестранта и способы их применения
TWI859990B (zh) 玻尿酸衍生物醫藥品組合物及醫藥品組合物
JP7470954B2 (ja) ナノ粒子の製造方法
BR112018072768B1 (pt) Suspensão, composição farmacêutica, método para formar uma suspensão fulvestrant aquosa e suspensão fulvestrant aquosa
HK40049829B (en) Aripiprazole prodrug compositions
HK40049829A (en) Aripiprazole prodrug compositions

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200319

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200319

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210126

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210422

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210616

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210928